Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis B.
With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms.
This industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. From dissecting safe induction of innate and adaptive immune pathways and elucidating the role of T-cells in clearing virus infections, to clinical progress in combination therapy and assessing durability of surface antigen seroclearance, don’t miss your chance to join the conversation.
Harness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences, Vir Biotechnology, VBI Vaccines, Altimmune, Drug Farm, Replicor and many more to guide your strategic decisions and drive clinical progress to achieve functional cure for chronic HBV.
Access the official agenda for more information.
Early bird & team discounts available – Secure your place today.
This post was originally published on Source Link